BACKGROUND: The clinical management of low-level viremia (LLV) remains unclear. The objective of this study was to investigate the association of blips and LLV with virologic failure. METHODS: We enlisted patients who newly enrolled into the HIV Research Network between 2005 and 2015, had HIV-1 RNA more than 200 copies/ml, and were either antiretroviral therapy (ART)-naive or ART-experienced and not on ART. Patients were included who achieved virologic suppression (≤50 on two consecutive viral loads) and had at least two viral loads following suppression. Blips and LLV (≥2 consecutive >51 copies/ml) were categorized separately into three categories: no blips/LLV, 51-200, 201-500. Cox proportional hazards regression was used to assess association between rates of blips/LLV and virologic failure (two consecutive >500). RESULTS: The 2795 patients were mostly male (75.4%), black (50.3%), and MSM (52.9%). Median age was 38 years old (interquartile range 29-48). Most patients (88.8%) were ART-naive at study entry. Overall, 283 (10.1%) patients experienced virologic failure. A total of 152 (5.4%) patients experienced LLV to 51-200 and 110 (3.9%) patients experienced LLV to 201-500. Both LLV 51-200 [adjusted hazard ratio (aHR) 1.83 (1.10,3.04)] and LLV 201-500 [aHR 4.26 (2.65,6.86)] were associated with virologic failure. In sensitivity analysis excluding ART-experienced patients, the association between LLV 51 and 200 and virologic failure was not statistically significant. CONCLUSION: LLV between 201 and 500 was associated with virologic failure, as was LLV between 51 and 200, particularly among ART-experienced patients. Patients with LLV below the current Department of Health and Human Services threshold for virologic failure (persistent viremia ≥200) may require more intensive monitoring because of increased risk for virologic failure.
BACKGROUND: The clinical management of low-level viremia (LLV) remains unclear. The objective of this study was to investigate the association of blips and LLV with virologic failure. METHODS: We enlisted patients who newly enrolled into the HIV Research Network between 2005 and 2015, had HIV-1 RNA more than 200 copies/ml, and were either antiretroviral therapy (ART)-naive or ART-experienced and not on ART. Patients were included who achieved virologic suppression (≤50 on two consecutive viral loads) and had at least two viral loads following suppression. Blips and LLV (≥2 consecutive >51 copies/ml) were categorized separately into three categories: no blips/LLV, 51-200, 201-500. Cox proportional hazards regression was used to assess association between rates of blips/LLV and virologic failure (two consecutive >500). RESULTS: The 2795 patients were mostly male (75.4%), black (50.3%), and MSM (52.9%). Median age was 38 years old (interquartile range 29-48). Most patients (88.8%) were ART-naive at study entry. Overall, 283 (10.1%) patients experienced virologic failure. A total of 152 (5.4%) patients experienced LLV to 51-200 and 110 (3.9%) patients experienced LLV to 201-500. Both LLV 51-200 [adjusted hazard ratio (aHR) 1.83 (1.10,3.04)] and LLV 201-500 [aHR 4.26 (2.65,6.86)] were associated with virologic failure. In sensitivity analysis excluding ART-experienced patients, the association between LLV 51 and 200 and virologic failure was not statistically significant. CONCLUSION: LLV between 201 and 500 was associated with virologic failure, as was LLV between 51 and 200, particularly among ART-experienced patients. Patients with LLV below the current Department of Health and Human Services threshold for virologic failure (persistent viremia ≥200) may require more intensive monitoring because of increased risk for virologic failure.
Authors: Antonia L Moore; Mike Youle; Marc Lipman; Alessandro Cozzi-Lepri; Fiona Lampe; Sarah Madge; Shrenee Nesaratnam; Mervyn Tyrer; Zoe Cuthbertson; Darren Ransom; Clive Loveday; Margaret A Johnson; Andrew N Phillips Journal: AIDS Date: 2002-03-08 Impact factor: 4.177
Authors: Gilbert Greub; Alessandro Cozzi-Lepri; Bruno Ledergerber; Schlomo Staszewski; Luc Perrin; Veronica Miller; Patrick Francioli; Hansjakob Furrer; Manuel Battegay; Pietro Vernazza; Enos Bernasconi; Huldrych F Günthard; Bernard Hirschel; Andrew N Phillips; Amalio Telenti Journal: AIDS Date: 2002-09-27 Impact factor: 4.177
Authors: Shoshana Y Kahana; Maria Isabel Fernandez; Patrick A Wilson; Jose A Bauermeister; Sonia Lee; Craig M Wilson; Lisa B Hightow-Weidman Journal: J Acquir Immune Defic Syndr Date: 2015-02-01 Impact factor: 3.731
Authors: Loren G Miller; Carol E Golin; Honghu Liu; Ron D Hays; Jenna Hua; Neil S Wenger; Andrew H Kaplan Journal: J Infect Dis Date: 2004-03-31 Impact factor: 5.226
Authors: Anna M Geretti; Colette Smith; Annette Haberl; Ana Garcia-Diaz; Gaia Nebbia; Margaret Johnson; Andrew Phillips; Schlomo Staszewski Journal: Antivir Ther Date: 2008
Authors: Carol E Golin; Honghu Liu; Ron D Hays; Loren G Miller; C Keith Beck; Jeanette Ickovics; Andrew H Kaplan; Neil S Wenger Journal: J Gen Intern Med Date: 2002-10 Impact factor: 5.128
Authors: Hanna Brattgård; Per Björkman; Piotr Nowak; Carl Johan Treutiger; Magnus Gisslén; Olof Elvstam Journal: PLoS One Date: 2022-05-17 Impact factor: 3.240